These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

111 related items for PubMed ID: 22340630

  • 1. Administration of cisplatin-based chemotherapy for advanced urothelial carcinoma in the community.
    Sonpavde G, Watson D, Tourtellott M, Cowey CL, Hellerstedt B, Hutson TE, Zhan F, Vogelzang NJ.
    Clin Genitourin Cancer; 2012 Mar; 10(1):1-5. PubMed ID: 22340630
    [Abstract] [Full Text] [Related]

  • 2. Phase II trial of carboplatin and paclitaxel in cisplatin-pretreated advanced transitional cell carcinoma: a Southwest Oncology Group study.
    Vaishampayan UN, Faulkner JR, Small EJ, Redman BG, Keiser WL, Petrylak DP, Crawford ED.
    Cancer; 2005 Oct 15; 104(8):1627-32. PubMed ID: 16138364
    [Abstract] [Full Text] [Related]

  • 3. Outcomes after adjuvant chemotherapy in the treatment of high-risk urothelial carcinoma of the upper urinary tract (UUT-UC): results from a large multicenter collaborative study.
    Vassilakopoulou M, de la Motte Rouge T, Colin P, Ouzzane A, Khayat D, Dimopoulos MA, Papadimitriou CA, Bamias A, Pignot G, Nouhaud FX, Hurel S, Guy L, Bigot P, Roumiguié M, Rouprêt M, French Collaborative National Database on UUT-UCC.
    Cancer; 2011 Dec 15; 117(24):5500-8. PubMed ID: 21638278
    [Abstract] [Full Text] [Related]

  • 4. Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium.
    Dreicer R, Manola J, Roth BJ, See WA, Kuross S, Edelman MJ, Hudes GR, Wilding G.
    Cancer; 2004 Apr 15; 100(8):1639-45. PubMed ID: 15073851
    [Abstract] [Full Text] [Related]

  • 5. Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC).
    Necchi A, Sonpavde G, Lo Vullo S, Giardiello D, Bamias A, Crabb SJ, Harshman LC, Bellmunt J, De Giorgi U, Sternberg CN, Cerbone L, Ladoire S, Wong YN, Yu EY, Chowdhury S, Niegisch G, Srinivas S, Vaishampayan UN, Pal SK, Agarwal N, Alva A, Baniel J, Golshayan AR, Morales-Barrera R, Bowles DW, Milowsky MI, Theodore C, Berthold DR, Daugaard G, Sridhar SS, Powles T, Rosenberg JE, Galsky MD, Mariani L, RISC Investigators.
    Eur Urol; 2017 Feb 15; 71(2):281-289. PubMed ID: 27726966
    [Abstract] [Full Text] [Related]

  • 6. Retrospective analysis of satraplatin in patients with metastatic urothelial cancer refractory to standard platinum-based chemotherapy.
    Galsky MD, Seng S, Camacho LH, Chiorean EG, Mulkerin D, Hong DS, Oh WK, Bajorin DF.
    Clin Genitourin Cancer; 2011 Sep 15; 9(1):27-30. PubMed ID: 21700509
    [Abstract] [Full Text] [Related]

  • 7. Prospective trial of ifosfamide, paclitaxel, and cisplatin in patients with advanced non-transitional cell carcinoma of the urothelial tract.
    Galsky MD, Iasonos A, Mironov S, Scattergood J, Donat SM, Bochner BH, Herr HW, Russo P, Boyle MG, Bajorin DF.
    Urology; 2007 Feb 15; 69(2):255-9. PubMed ID: 17320659
    [Abstract] [Full Text] [Related]

  • 8. Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel.
    Hoskins P, Vergote I, Cervantes A, Tu D, Stuart G, Zola P, Poveda A, Provencher D, Katsaros D, Ojeda B, Ghatage P, Grimshaw R, Casado A, Elit L, Mendiola C, Sugimoto A, D'Hondt V, Oza A, Germa JR, Roy M, Brotto L, Chen D, Eisenhauer EA.
    J Natl Cancer Inst; 2010 Oct 20; 102(20):1547-56. PubMed ID: 20937992
    [Abstract] [Full Text] [Related]

  • 9. Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy.
    George L, Bladou F, Bardou VJ, Gravis G, Tallet A, Alzieu C, Serment G, Salem N.
    Urology; 2004 Sep 20; 64(3):488-93. PubMed ID: 15351577
    [Abstract] [Full Text] [Related]

  • 10. Salvage chemotherapy with paclitaxel, ifosfamide, and nedaplatin in patients with urothelial cancer who had received prior cisplatin-based therapy.
    Shinohara N, Harabayashi T, Suzuki S, Nagao K, Seki H, Murakumo M, Mitsuhashi K, Demura T, Nagamori S, Matsuyama H, Naito K, Nonomura K.
    Cancer Chemother Pharmacol; 2006 Sep 20; 58(3):402-7. PubMed ID: 16416335
    [Abstract] [Full Text] [Related]

  • 11. Adjuvant chemotherapy for invasive urothelial cancer: experience with a methotrexate, vincristine, cisplatin, cyclophosphamide, adriamycin and bleomycin (MVP-CAB) regimen: a preliminary report.
    Gohji K, Higuchi A, Maruyama S, Minayoshi K, Fujii A, Itoh N, Hasunuma Y, Tanaka H, Izumi T.
    Jpn J Clin Oncol; 1993 Oct 20; 23(5):291-8. PubMed ID: 7693990
    [Abstract] [Full Text] [Related]

  • 12. [Combination chemotherapy of cyclophosphamide, adriamycin and cisplatin in advanced urothelial cancer].
    Nakagawa S, Nakao M, Toyoda K, Nukui M, Takada H, Ebisui K, Watanabe H, Furusawa T, Maegawa M, Kaiho H.
    Gan To Kagaku Ryoho; 1987 Nov 20; 14(11):3071-7. PubMed ID: 3674892
    [Abstract] [Full Text] [Related]

  • 13. Paclitaxel Carboplatin chemotherapy as a second-line chemotherapy for advanced platinum resistant urothelial cancer in Japanese cases.
    Soga N, Onishi T, Arima K, Sugimura Y.
    Int J Urol; 2007 Sep 20; 14(9):828-32. PubMed ID: 17760750
    [Abstract] [Full Text] [Related]

  • 14. Phase II trial of weekly paclitaxel and carboplatin chemotherapy in patients with advanced transitional cell cancer.
    Johannsen M, Sachs M, Roigas J, Hinke A, Staack A, Loening SA, Schnorr D, Wille AH.
    Eur Urol; 2005 Aug 20; 48(2):246-51. PubMed ID: 15963636
    [Abstract] [Full Text] [Related]

  • 15. Predictive factors for response and prognostic factors for long-term survival in consecutive, single institution patients with locally advanced and/or metastatic transitional cell carcinoma following cisplatin-based chemotherapy.
    Jessen C, Agerbaek M, Von Der Maase H.
    Acta Oncol; 2009 Aug 20; 48(3):411-7. PubMed ID: 18798018
    [Abstract] [Full Text] [Related]

  • 16. Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract: final report of a phase II trial evaluating two dosing schedules.
    Bajorin DF, McCaffrey JA, Dodd PM, Hilton S, Mazumdar M, Kelly WK, Herr H, Scher HI, Icasiano E, Higgins G.
    Cancer; 2000 Apr 01; 88(7):1671-8. PubMed ID: 10738226
    [Abstract] [Full Text] [Related]

  • 17. Posttreatment prognostic nomogram for patients with metastatic urothelial cancer completing first-line cisplatin-based chemotherapy.
    Galsky MD, Moshier E, Krege S, Lin CC, Hahn N, Ecke T, Sonpavde G, Pond G, Godbold J, Oh WK, Bamias A.
    Urol Oncol; 2014 Jan 01; 32(1):48.e1-8. PubMed ID: 24055428
    [Abstract] [Full Text] [Related]

  • 18. Combination chemotherapy with carboplatin and methotrexate in the treatment of advanced urothelial carcinoma. A phase II study.
    Dogliotti L, Bertetto O, Berruti A, Clerico M, Fanchini L, Sicora W, Faggiuolo R.
    Am J Clin Oncol; 1995 Feb 01; 18(1):78-82. PubMed ID: 7847264
    [Abstract] [Full Text] [Related]

  • 19. The role of chemotherapy in the treatment of urothelial cell carcinoma of the upper urinary tract (UUT-UCC).
    Audenet F, Yates DR, Cussenot O, Rouprêt M.
    Urol Oncol; 2013 May 01; 31(4):407-13. PubMed ID: 20884249
    [Abstract] [Full Text] [Related]

  • 20. Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma.
    Galsky MD, Chen GJ, Oh WK, Bellmunt J, Roth BJ, Petrioli R, Dogliotti L, Dreicer R, Sonpavde G.
    Ann Oncol; 2012 Feb 01; 23(2):406-10. PubMed ID: 21543626
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.